We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 03, 2021

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients

Journal of the National Cancer Institute

 

Additional Info

Journal of the National Cancer Institute
Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
J. Natl. Cancer Inst 2021 Jun 08;[EPub Ahead of Print], GM Dackus, K Jóźwiak, GS Sonke, E van der Wall, PJ van Diest, S Siesling, M Hauptmann, SC Linn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading